Impact of high-throughput screening in biomedical research
The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
Abstract
High-throughput screening (HTS) has been postulated in several quarters to be a contributory factor to the decline in productivity in the pharmaceutical industry. Moreover, it has been blamed for stifling the creativity that drug discovery demands. In this article, we aim to dispel these myths and present the case for the use of HTS as part of a proven scientific tool kit, the wider use of which is essential for the discovery of new chemotypes.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Cell-based phenotypic screening of chemical libraries represents a powerful tool to identify new potential drugs48.”
From Identification and characterization of Cardiac Glycosides as senolytic compounds (2019) · cites this paper as [48]
Citations
Cites
Zhang, J.-H., Chung, T. D. Y., & Oldenburg, K. R. (1999) · SLAS Discovery · doi:10.1177/108705719900400206 · Cited by 6,847 · cited 1×
“HTS laboratories have pioneered and implemented rigorous quality assurance methods, such as Z′ trend monitoring”
MethodCan the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
How to improve R&D productivity: the pharmaceutical industry's grand challenge
Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3078 · Cited by 3,566 · cited 1×
“These efforts typically take 2–3 years in most drug discovery companie”
BackgroundDrug repositioning: identifying and developing new uses for existing drugs
Ashburn, T. T., & Thor, K. B. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1468 · Cited by 3,237 · cited 1×
“There have been numerous analyses of pharmaceutical industry productivity, and several of these have blamed high-throughput screening (HTS) as a factor undermining the creativity that has sustained the industry over the past centur”
BackgroundDiscovery and development of sorafenib: a multikinase inhibitor for treating cancer
Wilhelm, S., Carter, C., Lynch, M., Lowinger, T., Dumas, J., Smith, R. A., Schwartz, B., Simantov, R., & Kelley, S. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2130 · Cited by 1,829
Lessons from 60 years of pharmaceutical innovation
Munos, B. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2961 · Cited by 1,207
Dorr, P., Westby, M., Dobbs, S., Griffin, P., Irvine, B., Macartney, M., Mori, J., Rickett, G., Smith-Burchnell, C., Napier, C., et al. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.11.4721-4732.2005 · Cited by 1,152
Hit and lead generation: beyond high-throughput screening
Bleicher, K. H., Böhm, H.-J., Müller, K., & Alanine, A. I. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1086 · Cited by 1,056
Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect
Gao, M., Nettles, R. E., Belema, M., Snyder, L. B., Nguyen, V. N., Fridell, R. A., Serrano-Wu, M. H., Langley, D. R., Sun, J.-H., O’Boyle II, D. R., et al. (2010) · Nature · doi:10.1038/nature08960 · Cited by 939 · cited 1×
“This approach was used to discover compounds that inhibited hepatitis C virus replication and, after consequent optimization, the approach yielded efficacious clinical candidates with a broad genotype coverag”
MethodA Specific Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase
Fry, D. W., Kraker, A. J., McMichael, A., Ambroso, L. A., Nelson, J. M., Leopold, W. R., Connors, R. W., & Bridges, A. J. (1994) · Science · doi:10.1126/science.8066447 · Cited by 806
Research works printed but not linked: 5
- Landers, P. Human Element: drug industry's big push into technology falls short — testing machines were built to streamline research — but may be stifling it — officials see payoff after 2010. The Wall Street Journal 1 (24 Feb 2004).
- Mullin, R. As high-throughput screening draws fire, researchers leverage science to put automation into perspective. Chem. Eng. News 82, 23–32 (2004).
- HTStec Limited. Cellular Assay Reagents Trends 2009 Report (Cambridge, UK, 2009).
- LaMattina, J. L. (ed.) in Drug Truths: Dispelling the Myths About Pharma R&D 65–66 (John Wiley and Sons, Inc., Hoboken, New Jersey, 2009).
- Inglese, J. in Ask the Expert Forum, ACS Chemical Biology. ACS Publications [online] http://community.acs.org/ChemBiol/AsktheExpert/AsktheExpertArchive/tabid/67/Default.aspx (2008).
Cited by
Items 901–1,000 of 1,000
High-Throughput Screening for Drug Discovery toward Infectious Diseases: Options and Challenges
Gupta, A., Kumar, S., Maurya, V. K., Puri, B., & Saxena, S. K. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.102936 · Cited by 5
Limonin as a Starting Point for the Construction of Compounds with High Scaffold Diversity
Furiassi, L., Tonogai, E. J., & Hergenrother, P. J. (2021) · Angewandte Chemie · doi:10.1002/ange.202104228 · Cited by 5
Mining Natural-Products Screening Data for Target-Class Chemical Motifs
Coma, I., Bandyopadhyay, D., Dı́ez, E., Álvarez-Ruíz, E., Frailes, M. T. D. L., & Colmenarejo, G. (2014) · SLAS DISCOVERY · doi:10.1177/1087057114521463 · Cited by 5
Evaluation of a Liquid Dispenser for Assay Development and Enzymology in 1536-Well Format
Butendeich, H., Pierret, N. M., & Numao, S. (2013) · SLAS TECHNOLOGY · doi:10.1177/2211068212472184 · Cited by 5
“A significant development in early drug discovery has been the high-throughput screen (HTS), in which a large number of compounds can be tested relatively quickly against a particular target/assay.(1) A key factor that enabled such a robust testing of millions of compounds has been the codevelopment of nanoliter liqui…”
BackgroundCellular Imaging in Drug Discovery: Imaging and Informatics for Complex Cell Biology
Li, Z., Cvijic, M. E., & Zhang, L. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.12328-5 · Cited by 5
Requirements of skin tissue models for high-throughput screening
Mathes, S. H., & Parker, C. N. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-810545-0.00018-8 · Cited by 5
Stable cellular models of nuclear receptor PXR for high-throughput evaluation of small molecules
Negi, S., Singh, S. K., Kumar, S., Kumar, S., & Tyagi, R. K. (2018) · Toxicology in Vitro · doi:10.1016/j.tiv.2018.06.017 · Cited by 5
Convolutional Neural Networks for Predicting Molecular Binding Affinity to HIV-1 Proteins
Morris, P., DaSilva, Y., Clark, E. A., Hahn, W. E., & Barenholtz, E. (2018) · ACM International Conference on Bioinformatics, Computational Biology, and Health Informatics (ACM-BCB) · doi:10.1145/3233547.3233596 · Cited by 5
“One of the most effective tools for small molecule discovery is high-throughput screening (HTS) [21], where thousands of molecules can be tested experimentally for binding affinity to a target protein.”
BackgroundFlow Chemistry in Drug Discovery
Alcázar, J., de la Hoz, A., & Díaz‐Ortiz, Á. (2019) · Royal Society of Chemistry eBooks · doi:10.1039/9781788016131-00053 · Cited by 5
High-throughput, low-cost reaction screening using a modified 3D printer
Schrader, R., Ayrton, S. T., Kaerner, A., & Cooks, R. G. (2019) · The Analyst · doi:10.1039/c9an00785g · Cited by 5
The Evolving Role of Structural Biology in Drug Discovery
Renaud, J. (2020) · Wiley eBooks · doi:10.1002/9781118681121.ch1 · Cited by 6
Fantel, A.-M., Myrianthopoulos, V., Georgoulis, A., Lougiakis, N., Zantza, I., Lambrinidis, G., Augsburger, F., Marakos, P., Vorgias, C. E., Szabó, C., et al. (2020) · Molecules · doi:10.3390/molecules25163739 · Cited by 5
“In this direction, exploring the available chemical space with the objective to discover new scaffolds that can act as promising leads for achieving potent and selective CBS is deemed a highly interesting screening endeavor [38].”
BackgroundChen, C., Patel, R., Bortolami, A., & Sesti, F. (2020) · PLoS ONE · doi:10.1371/journal.pone.0240255 · Cited by 5
“These high-throughput screening assays are cost- and time-efficient but generally unable to recapitulate the complex physiology a compound is likely to encounter in a whole animal [1].”
BackgroundBiswas, S. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.594750 · Cited by 6
“These measurements from high-throughput target-directed screens have been widely used for their potential application in drug discovery through unbiased testing of several million compounds per screen (Macarron et al., 2011).”
MethodKraus, J. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.01.009 · Cited by 5
Surface plasmon resonance coupled to mass spectrometry in bioanalysis
Xue, J., & Liu, H. (2021) · Comprehensive analytical chemistry · doi:10.1016/bs.coac.2021.08.001 · Cited by 5
Bhattarai, S., Kumar, R., Nag, S., & Namasivayam, V. (2022) · Springer eBooks · doi:10.1007/978-981-16-5993-5_2 · Cited by 6
Crocetti, L., Floresta, G., Nazir, S., Vergelli, C., Bhogal, A., Biancalani, C., Cesari, N., Giovannoni, M. P., & Cilibrizzi, A. (2022) · Structural Chemistry · doi:10.1007/s11224-022-01889-0 · Cited by 9
“In medicinal chemistry, heterocyclic structures offer the advantage of generating molecular libraries based on a specific core scaffold, permitting screening tests and structure–activity relationship (SAR) studies for the targets of interest [3].”
BackgroundI-LIFT (image-based laser-induced forward transfer) platform for manipulating encoded microparticles
Lee, S., Lee, W., Lee, A. C., Nam, J., Lee, J., Kim, H., Jeong, Y., Yeom, H., Kim, N., Song, S. W., et al. (2022) · Biomicrofluidics · doi:10.1063/5.0131733 · Cited by 5
Pals, M. J., & Velema, W. A. (2023) · Angewandte Chemie · doi:10.1002/ange.202302796 · Cited by 5
High Throughput Technology: Exemplary Highlights of Advanced Technical Tools
Titlbach, S., Futter, C., Lejkowski, M. L., de Oliveira, A. L., & Schunk, S. A. (2014) · Chemie Ingenieur Technik · doi:10.1002/cite.201400019 · Cited by 5
Detection of bond formations by DNA-programmed chemical reactions and PCR amplification
Li, Y., Zhang, M., Zhang, C., & Li, X. (2012) · Chemical Communications · doi:10.1039/c2cc35230c · Cited by 6
Physics and Its Interfaces with Medicinal Chemistry and Drug Design
dos Santos, R. N., & Andricopulo, A. D. (2013) · Brazilian Journal of Physics · doi:10.1007/s13538-013-0149-7 · Cited by 5
Kernel Methods for Predicting Yields of Chemical ReactionsPreprint
Haywood, A. L., Redshaw, J., Hanson‐Heine, M. W. D., Taylor, A., Brown, A., Mason, A., Gaertner, T., & Hirst, J. D. (2021) · ChemRxiv · doi:10.26434/chemrxiv.14346920 · Cited by 5
High-throughput computational screening for lead discovery and development
Shaik, N. S., & Balya, H. (2025) · Advances in pharmacology · doi:10.1016/bs.apha.2025.01.001 · Cited by 5
Song, G., Deng, M., Chen, Y., Jia, S., & Nie, Z. (2025) · IEEE Journal of Biomedical and Health Informatics · doi:10.1109/jbhi.2025.3547741 · Cited by 4
Chen, G., Liao, J.-B., Yu, Y., Le, K., Zhao, H., Qin, Y.-Y., Cai, L., & Sheng, R. (2025) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.5c01753 · Cited by 4
Machine learning-guided optimization of triple agonist peptide therapeutics for metabolic disease
Wong, A., Guduri, S., Chen, T.-Y., & Patel, K. (2025) · Frontiers in Bioinformatics · doi:10.3389/fbinf.2025.1687617 · Cited by 4
AI Guided Protein Design for Next‐Generation Autogenic Engineered Living Materials
Hammad, H. M., & Duraj‐Thatte, A. (2026) · Advanced Intelligent Systems · doi:10.1002/aisy.202501021 · Cited by 6
“[58,59] Such infrastructure will need to be paired with clear safety protocols and evolving regulatory frameworks speci fi c to ELMs.”
Yu, S., Peng, Q., Wei, W., Li, X., & Long, S. (2026) · npj Precision Oncology · doi:10.1038/s41698-026-01296-2 · Cited by 5
Artificial Intelligence Across the Drug Development Lifecycle
Demyashkin, G. A., Алексеевич, П. М., Zyryanov, S., Yavorskiy, A., Shegai, P., & Kaprin, A. (2026) · Medical Sciences · doi:10.3390/medsci14020248 · Cited by 6
“The 1990s marked a transformation from the theoretical basis of QSAR toward the practical approaches of the first “Big Data” wave in pharmacology (it was catalyzed by the industrialization of high-throughput screening (HTS) and combinatorial chemistry) [69,70].”
Nakadate, K., Ito, N., & Kawakami, K. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27104330 · Cited by 5
“Molecular and cell-based assays are essential instruments in the early stages of drug discovery, facilitating the rapid identification of candidate compounds and the elucidation of proximal mechanisms of action [80].”
Natural Products in Modern Drug Discovery: Advances, Challenges and Emerging Technologies
Papadopoulou, S. Κ., Poulios, E., Tsopelas, F. N., Tsantili‐Kakoulidou, A., & Giaginis, C. (2026) · Scientia Pharmaceutica · doi:10.3390/scipharm94030061 · Cited by 6
“Concurrently, the rise of combinatorial chemistry and high-throughput screening (HTS) fostered a shift toward synthetic compound libraries, which promised rapid generation and screening of vast numbers of molecules [16].”
InfluentialPhenoDEL: A Novel Screening Strategy Based on Intracellular Protein Degradation Activity
Onda, Y., Ochi, Y., Araki, T., Kageoka, M., Takeda, S., Yamada, K., Ueda, T., Ohno, K., Tanaka, M., Sakai, D., et al. (2026) · ACS Chemical Biology · doi:10.1021/acschembio.6c00234 · Cited by 4
Laboratory Techniques in Cellular and Molecular Medicine
Ed., J. S., Janošťáková, A., Das, V., Kudlová, N., Stránská, J., Buriánová, R., Kotulová, J., Schadich, E., Ondra, M., Kubíčková, A., et al. (2022) · doi:10.5507/lf.22.24460499 · Cited by 8
In Silico Structure-Based Vaccine Design
Piplani, S., Winkler, D. A., Honda‐Okubo, Y., Khanna, V., & Petrovsky, N. (2023) · Methods in molecular biology · doi:10.1007/978-1-0716-3239-0_26 · Cited by 4
Advances in the approaches used to repurpose drugs for neuroblastoma
Miera-Maluenda, M., Pérez-Torres, M., Mañas, A., Rubio‐San‐Simón, A., Butjosa-Espín, M., Ruiz-Duran, P., Seoane, J. A., Moreno, L., & Segura, M. F. (2024) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2024.2402413 · Cited by 4
“…by measuring: a) changes in the rotation of fluorescently labeled molecules upon binding (fluorescence polarization); b) changes in refractive index near a sensor surface upon binding (surface plasmon resonance); c) heat changes upon binding interactions (isothermal titration calori-metry) [52–54].”
Mehmood, A., Ali, M. S., Li, D., Kaushik, A. C., & Wei, D. (2024) · Chemical Biology & Drug Design · doi:10.1111/cbdd.14627 · Cited by 4
“Such in vitro systems have been instrumental in identifying numerous biomarkers for anticancer therapy, as evidenced by the discovery of various clinically approved biomarkers through pharmacogenomic studies (Macarron et al. 2011).”
Evaluating AutoGrow4 – an open-source toolkit for semi-automated computer-aided drug discovery
Bassani, D., Pavan, M., & Moro, S. (2025) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2025.2499122 · Cited by 4
Innovations in cancer treatment: evaluating drug resistance with lab-on-a-chip technologies
Heydari, P., Javaherchi, P., Samadzadeh, M., Azadani, R. N., Rad, A. B., Zarepour, A., Khosravi, A., Iravani, S., & Zarrabi, A. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.125936 · Cited by 5
Fuchs, N. S., Kuncewicz, K., Gaamouch, F. E., & Gabr, M. T. (2025) · SLAS DISCOVERY · doi:10.1016/j.slasd.2025.100255 · Cited by 4
A Heuristic Algorithm for Plate SelectionThat Maximizes Compound Diversity
Zhu, H., Klug-McLeod, J. L., & Bakken, G. A. (2013) · Croatica Chemica Acta · doi:10.5562/cca2301 · Cited by 4
Establishing and Maintaining a Robust Sample Management System
Janzen, W. P., Admirand, E. A., Andrews, J., Boeckeler, M., Jayakody, C., Majer, C. R., Porwal, G., Sana, S., Unkuri, S., & Zaayenga, A. (2019) · SLAS TECHNOLOGY · doi:10.1177/2472630319834471 · Cited by 4
Self-citationA Note on Robotics and Artificial Intelligence in Pharmacy
Bhattacharya, S. (2021) · Applied Drug Research Clinical Trials and Regulatory Affairs · doi:10.2174/2667337108666211206151551 · Cited by 6
Wei, Z., Wang, Z., & Tang, C. (2025) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.4c02348 · Cited by 4
Managing missing measurements in small-molecule screens
Browning, M. R., Calhoun, B. T., & Swamidass, S. J. (2013) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-013-9642-x · Cited by 4
Opportunities and Challenges for Innovation in Pharmaceuticals: Now or Never!
Barreiro, E. J., & Pinto, A. C. (2013) · Revista Virtual de Química · doi:10.5935/1984-6835.20130078 · Cited by 4
Alajlani, M. M., & Backlund, A. (2020) · Molecules · doi:10.3390/molecules25040945 · Cited by 4
“The approach of the hit-and-trail method has limited the screening strategies to their known chemical moieties and with an extremely poor hit rate [14,15].”
MethodA look around the West Indies: The spices of life are secondary metabolites
Demeritte, A. R., & Wuest, W. M. (2020) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2020.115792 · Cited by 4
Mathai, N., Stork, C., & Kirchmair, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22157773 · Cited by 4
“A key strategy to identify bioactive compounds for biomacromolecules of interest is to screen large collections of compounds with biochemical or cell-based assays [1].”
BackgroundNatural Products as Potential Antiviral Drugs: The Specific Case of Marine Biotoxins
Kraus, J. (2021) · Russian Journal of Bioorganic Chemistry · doi:10.1134/s1068162021060133 · Cited by 4
IMI European Lead Factory — democratizing access to high-throughput screening
Jones, P. S., Boucharens, S., McElroy, S. P., Morrison, A. J., Honarnejad, S., van Boeckel, S., van den Hurk, H., Basting, D., Hüser, J., Jaroch, S., et al. (2021) · Nature Reviews Drug Discovery · doi:10.1038/d41573-021-00196-3 · Cited by 4
Queme, B., Braisted, J. C., Dranchak, P. K., & Inglese, J. (2023) · Journal of Cheminformatics · doi:10.1186/s13321-023-00717-9 · Cited by 4
“…concentration, was made possible by developments in assay technology, instrumentation, microtiter plate designs, and both commoditization and academic interest in chemical library generation [2–5]. qHTS has been applied to enzymes, receptors, and biological processes using diverse libraries [6–8].”
MethodCell-based assays in high-throughput mode (HTS)
Rajalingham, K. (2016) · Biotechnologia · doi:10.5114/bta.2016.62927 · Cited by 4
“…minimize the number of animals sacrificed to experimentation, costs (cryopreserved mice, for instance, costs $ 2525.00 USD and have a high maintenance cost in specialized and expensive facilities), and time (to raise, feed, etc.) (Breier et al., 2008; Macarron et al., 2011; Szymański et al., 2011).”
BackgroundInfluentialPetersen, R. G., Quement, S. T. L., & Nielsen, T. E. (2014) · Angewandte Chemie · doi:10.1002/ange.201405747 · Cited by 5
Medicinal Chemistry Approaches to Neglected Diseases Drug Discovery
Andricopulo, A. D., & Ferreira, L. L. G. (2014) · Journal of Modern Medicinal Chemistry · doi:10.12970/2308-8044.2014.02.01.4 · Cited by 6
Method for the Rapid Screening of Drug Candidates Using Single‐Protein Tracking in a Living Cell
Kim, D., Kim, Y. S., Kim, C. S., & Lee, N. K. (2020) · Bulletin of the Korean Chemical Society · doi:10.1002/bkcs.12198 · Cited by 4
Drug discovery and development
Palanki, R., & Bose, S. K. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-90300-4.00089-6 · Cited by 5
Development of novel therapeutic approaches for the reduction of apolipoprotein B expression
Mclaughlin, C. (2014) · Figshare · doi:10.13140/rg.2.1.3104.7840 · Cited by 5
Technology: Networks and Maps in Creativity Research, 1999–2018
Zhang, W., & Jiang, Y. Y. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-809324-5.23857-1 · Cited by 4
Ohue, M., Ii, R., Yanagisawa, K., & AKIYAMA, Y. (2019) · arXiv (Cornell University) · doi:10.48550/arxiv.1907.01103 · Cited by 7
“Highthroughput screening methods for screening compounds that show activity against proteins targeted by drug discovery from large-scale compound libraries are popular [2]; however, screening vast numbers of compounds is expensive.”
BackgroundNasibov, T. F., Gorokhova, A. V., Brazovsky, K. S., Porokhova, E. D., Avdeeva, E. Y., Белоусов, М. В., & Хлусов, И. А. (2025) · Advanced targets in Biomedicine · doi:10.5922/atb-2025-1-1-1 · Cited by 3
Peralta-Moreno, M. N., Granadino‐Roldán, J. M., Belenguer, M. S. T., & Rubio, J. (2025) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.5c02122 · Cited by 3
Kang, M., Yang, Z., Tian, Y., Li, D., Wang, Z., & Chen, L. (2025) · Discover Oncology · doi:10.1007/s12672-025-03970-6 · Cited by 3
“ML algorithms can be used for monotherapy prediction, outputting individual patient-specific treatment advice [94, 95].”
Novel liquid-based approaches for transmucosal drug delivery
van Staden, D., Lemmer, H. J. R., Liebenberg, W., & Hamman, J. H. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.12.042 · Cited by 3
“…practice which evolved into a competitive modern science employing sophisticated technologies such as computer-aided design of drugs, combinatorial chemistry, establishing relationships between drug activity and molecular structure, high-throughput screening and artificial intelligence 1 — 4 .”
Peptide-Polymer Conjugates as Model Systems To Explore the Functional Space of Precision Polymers
ten Brummelhuis, N., Wieczorek, S., Wilke, P., Schwemmer, T., & Börner, H. G. (2014) · ACS symposium series · doi:10.1021/bk-2014-1170.ch004 · Cited by 3
The iterative application of a large chemical space in the drug discovery process
Savych, O., Gryniukova, A. V., Alieksieieva, D. O., Dziuba, I., Borysko, P., Dudenko, D., Броварец, В. С., & Moroz, Y. S. (2021) · Journal of organic and pharmaceutical chemistry · doi:10.24959/ophcj.21.244362 · Cited by 3
Cheng, A. V., & Wuest, W. M. (2020) · ACS in focus · doi:10.1021/acs.infocus.7e4006 · Cited by 3
Exploring the Intersection of Omics Technologies and Biotechnology in Drug Interaction Studies
Quiroz, I. V. (2024) · Recent advances in biotechnology · doi:10.2174/9789815223163124090011 · Cited by 3
Creating a more strategic small molecule biophysical hit characterization workflow
Fotsch, C. H., Basu, D., Case, R. B., Chen, Q., Koneru, P. C., Lo, M.-C., Ngo, R., Sharma, P., Vaish, A., Yi, X., et al. (2024) · SLAS DISCOVERY · doi:10.1016/j.slasd.2024.100159 · Cited by 3
Karczewska, N., Pyc, M., Żukowski, K., Kosman, J., Kwiatek, D., & Kolanowski, J. L. (2024) · Postępy Biochemii · doi:10.18388/pb.2021_528 · Cited by 3
Kim, S. O., Yun, S. R., Lee, H., Jo, J., Ahn, D., Kim, D., Kosheleva, I., Henning, R. W., Kim, J., Kim, C., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-50696-0 · Cited by 3
“A wealth of techniques, from site-directed mutagenesis to high-throughput screening in diverse chemical libraries has enriched our understanding of protein functions, revealing regulatory pathways, unveiling protein-protein interactions, and identifying promising drug targets 1 – 5 .”
Immunobiology and pharmacology of neuropeptide substance P
Aslam, E., Gijasi, A., Perner, C., van Wijk, R. C., Märtson, A., van Westen, G. J. P., Bot, I., Heitman, L. H., & Mashaghi, A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-22194-1.00001-x · Cited by 3
CoDNet: controlled diffusion network for structure-based drug design
Kazi, F., Haque, S. Y., Jahan, E., Chakma, L., Shermin, T., Ahmed, A., Islam, S., Shatabda, S., & Azim, R. (2024) · Bioinformatics Advances · doi:10.1093/bioadv/vbaf031 · Cited by 5
“Traditional approaches involved identifying lead compounds through high-throughput screening, where a large number of compounds with particular biological activities are systematically tested in laboratory settings (Macarron et al. 2011, Blay et al. 2020).”
Navigating chemical space: multi-level Bayesian optimization with hierarchical coarse-graining
Walter, L. J., & Bereau, T. (2025) · Chemical Science · doi:10.1039/d5sc03855c · Cited by 4
Zhang, J., Lee, J., Wang, L., Zheng, Y., Wang, W., Guo, J., & Gao, J. (2017) · Analytical Methods · doi:10.1039/c6ay03406c · Cited by 3
Quantitative High‐Throughput Screening Using a Coincidence Reporter Biocircuit
Schuck, B. W., MacArthur, R., & Inglese, J. (2017) · Current Protocols in Neuroscience · doi:10.1002/cpns.27 · Cited by 3
“79:5.32.1-5.32.27. doi: 10.1002/cpns.27 INTRODUCTION High-throughput screening (HTS) has been used for many years in the pharmaceutical industry to identify therapeutic compounds for the treatment of human disease (Macarron et al., 2011).”
BackgroundInfluentialParallel Chemistry Approach to Identify Novel Nuclear Receptor Ligands Based on the GW0742 Scaffold
Teske, K. A., Rai, G., Nandhikonda, P., Sidhu, P. S., Feleke, B., Simeonov, A. M., Yasgar, A., Jadhav, A., Maloney, D. J., & Arnold, L. A. (2017) · ACS Combinatorial Science · doi:10.1021/acscombsci.7b00066 · Cited by 3
“The resulting esters were then cleaved with trifluoroacetic acid in CH2Cl2 to afford the final carboxylic acid products (1-78).”
MethodNovel Biomimetic Microphysiological Systems for Tissue Regeneration and Disease Modeling
Budhwani, K. I., Oliver, P. G., Buchsbaum, D. J., & Thomas, V. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-981-13-0947-2_6 · Cited by 3
Heil, C. (2019) · Open Biology · doi:10.1098/rsob.180145 · Cited by 3
RetractedPogodin, P. V., Lagunin, A. A., Filimonov, D. A., Nicklaus, M. C., & Poroikov, V. (2019) · SAR and QSAR in environmental research · doi:10.1080/1062936x.2019.1665580 · Cited by 3
“These two main trends shape the landscape of known chemical-biological interactions: increasing the experimental screening capacity [13] and rational selection of the chemical compounds for testing [14].”
BackgroundPurifyR: An R Package for Highly Automated, Reproducible Variable Extraction and Standardization
Omta, W. A., van Heesbeen, R. G. H. P., Shen, I., Feelders, A., Brinkhuis, M. J. S., Egan, D. A., & Spruit, M. R. (2020) · Systems Medicine · doi:10.1089/sysm.2019.0007 · Cited by 4
Development of FRET‐based high‐throughput screening for viral RNase III inhibitors
Wang, L., Saarela, J., Poque, S., & Valkonen, J. P. T. (2020) · Molecular Plant Pathology · doi:10.1111/mpp.12942 · Cited by 3
“An effective HTS assay is necessary for screening libraries of compounds to identify candidate inhibitors of enzyme activities (Macarron et al., 2011).”
MethodElectrochemical live cell patterning
Hur, W., Son, S. E., & Seong, G. H. (2020) · Electrochemistry Communications · doi:10.1016/j.elecom.2020.106778 · Cited by 3
Development and Application of Activity-based Fluorescent Probes for High-Throughput Screening
Li, X., & Cheng, J. (2021) · Current Medicinal Chemistry · doi:10.2174/0929867328666210525141728 · Cited by 3
Alamgir, A. N. M. (2018) · Progress in drug research · doi:10.1007/978-3-319-92387-1_1 · Cited by 3
A domain-label-guided translation model for molecular optimization
Zhang, Y., Tong, Y., Xia, X., Wu, Q.-W., & Su, Y. (2024) · Methods · doi:10.1016/j.ymeth.2024.02.005 · Cited by 4
Wang, Z., Xu, S., Fang, S., Cong, L., Dai, L., Huang, W., Liu, Z., Zheng, L., Xiang, J., Xiang, J., et al. (2024) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2024.135683 · Cited by 4
Rama-Garda, R., Domínguez, E., Loza, M. I., Lallena, M. J., de Blas, J., Toledo, M. Á., & Haro, R. (2024) · Assay and Drug Development Technologies · doi:10.1089/adt.2024.010 · Cited by 3
Computational and Experimental Approaches to Decipher the Complexity of Diseases
Rathod, S., Shinde, S., Choudhari, P. B., Dhavale, R. P., & Sarkate, A. P. (2024) · Springer eBooks · doi:10.1007/978-981-99-9462-5_15 · Cited by 5
Accelerated Screening of Protein–Ligand Interactions via Parallel T2-Weighted 19F-MRI
Faderl, D., Chenakkara, A., Jouda, M., MacKinnon, N., Gossert, A. D., & Korvink, J. G. (2024) · Analytical Chemistry · doi:10.1021/acs.analchem.4c00333 · Cited by 3
Drug Repurposing: Finding New Therapeutic Uses for Existing Pharmaceuticals
Nair, R. (2024) · Universal Research Reports · doi:10.36676/urr.v11.i3.1285 · Cited by 3
Borah, N. K., Tripathi, Y., Parashar, A., Santoshi, S., & Bansal, H. (2024) · Springer eBooks · doi:10.1007/978-981-97-4909-6_18 · Cited by 3
Gode, D., Schmitt, C., Engel, M., & Volmer, D. A. (2014) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-014-7703-1 · Cited by 3
Current approaches for the discovery of drugs that deter substance and drug abuse
Yasgar, A., & Simeonov, A. M. (2014) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2014.956721 · Cited by 3
“With its ability to speed up the discovery of drug candidates and lower overall costs, high-throughput screening (HTS) plays an important role in the process [16].”
BackgroundHas discovery-based cancer research been a bust?
Epstein, R. J. (2013) · Clinical & Translational Oncology · doi:10.1007/s12094-013-1071-8 · Cited by 3
“Although the advent of high-throughput screening is in no way to blame for this R&D crisis [12], it has thus far failed to prevent it.”
BackgroundSystematic design of analogs of active compounds covering more than 1000 targets
Dimova, D., & Bajorath, J. (2016) · MedChemComm · doi:10.1039/c5md00585j · Cited by 3
Compound Prioritization in Single-Concentration Screening Data Using Ligand Efficiency Indexes
Colmenarejo, G. (2016) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.6b00299 · Cited by 3
L’innovation thérapeutique : évolution et tendances
Meunier, B. (2015) · Collège de France eBooks · doi:10.4000/books.cdf.4438 · Cited by 3
Using Fragment Based Drug Discovery to Target Epigenetic Regulators in Cancer
Young, D. W. (2017) · MOJ Bioequivalence & Bioavailability · doi:10.15406/mojbb.2017.04.00062 · Cited by 3
Metadata
- Authors
- Macarron, R., Banks, M. N., Bojanic, D., Burns, D. J., Cirovic, D. A., Garyantes, T., Green, D. V. S., Hertzberg, R. P., Janzen, W. P., Paslay, J. W., Schopfer, U., & Sittampalam, G. S.
- Affiliations
- Bristol-Myers Squibb (United States) (US)
- Novartis (United States) (US)
- Abbott (United States) (US)
- Sanofi (France) (FR)
- GlaxoSmithKline (United Kingdom) (GB)
- GlaxoSmithKline (United States) (US)
- University of North Carolina at Chapel Hill (US)
- The University of Kansas Cancer Center (US)
- Novartis (Switzerland) (CH)
- Pfizer (United States) (US)
- Venue
- Nature Reviews Drug Discovery
- Published
- 2011-03
- Volume
- 10
- Issue
- 3
- Pages
- 188-195
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2031441006
- Cited by
- 1,364
- References
- 65
- Citations by year
- 2026: 113 · 2025: 117 · 2024: 99 · 2023: 103 · 2022: 82 · 2021: 107 · 2020: 106 · 2019: 77 · 2018: 105 · 2017: 87 · 2016: 96 · 2015: 64 · 2014: 61 · 2013: 73 · 2012: 54
- FWCI
- 6.80
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
- Keywords
- high-throughput screening, drug discovery, chemical biology
- MeSH terms
- Animals, Drug Evaluation, Preclinical, Humans, Drug Design, Biomedical Research, Small Molecule Libraries
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.